Lisata Therapeutics, Inc.
LSTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $70 | $0 | $1,000 |
| % Growth | -100% | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $70 | $0 | $1,000 |
| % Margin | – | 100% | – | 100% |
| R&D Expenses | $1,959 | $2,253 | $2,602 | $2,950 |
| G&A Expenses | $2,455 | $2,685 | $3,245 | $2,999 |
| SG&A Expenses | $2,455 | $2,685 | $3,245 | $2,999 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,414 | $4,938 | $5,847 | $5,949 |
| Operating Income | -$4,414 | -$4,868 | -$5,847 | -$4,949 |
| % Margin | – | -6,954.3% | – | -494.9% |
| Other Income/Exp. Net | $165 | $209 | $161 | $339 |
| Pre-Tax Income | -$4,249 | -$4,659 | -$5,686 | -$4,610 |
| Tax Expense | $0 | $0 | -$962 | $0 |
| Net Income | -$4,249 | -$4,659 | -$4,724 | -$4,610 |
| % Margin | – | -6,655.7% | – | -461% |
| EPS | -0.49 | -0.54 | -0.55 | -0.55 |
| % Growth | 9.3% | 1.8% | 0% | – |
| EPS Diluted | -0.49 | -0.54 | -0.55 | -0.55 |
| Weighted Avg Shares Out | 8,738 | 8,605 | 8,602 | 8,329 |
| Weighted Avg Shares Out Dil | 8,738 | 8,605 | 8,602 | 8,329 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $216 | $266 | $350 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $44 | $44 | $43 | $41 |
| EBITDA | -$4,205 | -$4,615 | -$5,804 | -$4,908 |
| % Margin | – | -6,592.9% | – | -490.8% |